Doximity, Inc. (DOCS) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $20.73 (+0.22%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 17, 2026 | Gene Mannheimer | Loop Capital Markets | $31.00 | +49.5% |
| Feb 9, 2026 | Richard Close | Canaccord Genuity | $34.00 | +64.0% |
| Feb 6, 2026 | Jailendra Singh | Truist Financial | $37.00 | +78.5% |
| Feb 6, 2026 | David Larsen | BTIG | $50.00 | +141.2% |
| Feb 6, 2026 | Scott Berg | Needham | $55.00 | +165.3% |
| Feb 6, 2026 | Jessica Tassan | Piper Sandler | $40.00 | +93.0% |
| Jan 20, 2026 | Stan Berenshteyn | Wells Fargo | $55.00 | +165.3% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $49.00 | +136.4% |
| Jan 8, 2026 | Jailendra Singh | Truist Financial | $62.00 | +199.1% |
| Jan 8, 2026 | Richard Close | Canaccord Genuity | $48.00 | +131.5% |
| Dec 8, 2025 | Glen Santangelo | Barclays | $63.00 | +203.9% |
| Oct 8, 2025 | Scott Schoenhaus | KeyBanc | $80.00 | +285.9% |
| Oct 1, 2025 | David Roman | Goldman Sachs | $64.00 | +208.7% |
| Sep 18, 2025 | Richard Close | Canaccord Genuity | $67.00 | +223.2% |
| May 20, 2025 | David Roman | Goldman Sachs | $50.00 | +141.2% |
| May 16, 2025 | Jailendra Singh | Truist Financial | $52.00 | +150.8% |
| May 16, 2025 | Brian Peterson | Raymond James | $65.00 | +213.6% |
| Jan 13, 2025 | Stan Berenshteyn | Wells Fargo | $43.00 | +107.4% |
| Jan 8, 2025 | Scott Schoenhaus | KeyBanc | $65.00 | +213.6% |
| Nov 14, 2024 | Jailendra Singh | Truist Financial | $49.00 | +136.4% |
Top Analysts Covering DOCS
DOCS vs Sector & Market
| Metric | DOCS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.47 | 2.24 | 2.41 |
| Analyst Count | 36 | 8 | 19 |
| Target Upside | +47.2% | +11475.0% | +17.1% |
| P/E Ratio | 20.84 | 4.01 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $153M | $154M | $155M | 10 |
| 2026-09-30 | $173M | $179M | $184M | 5 |
| 2026-12-31 | $195M | $202M | $208M | 5 |
| 2027-03-31 | $157M | $162M | $167M | 5 |
| 2027-06-30 | $161M | $167M | $171M | 5 |
| 2027-09-30 | $182M | $188M | $193M | 5 |
| 2027-12-31 | $208M | $215M | $221M | 5 |
| 2028-03-31 | $169M | $175M | $180M | 4 |
| 2029-03-31 | $824M | $824M | $824M | 3 |
| 2030-03-31 | $954M | $989M | $1.02B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.31 | $0.34 | $0.37 | 10 |
| 2026-09-30 | $0.41 | $0.43 | $0.44 | 4 |
| 2026-12-31 | $0.47 | $0.49 | $0.51 | 4 |
| 2027-03-31 | $0.33 | $0.35 | $0.36 | 4 |
| 2027-06-30 | $0.38 | $0.40 | $0.41 | 4 |
| 2027-09-30 | $0.40 | $0.42 | $0.44 | 4 |
| 2027-12-31 | $0.49 | $0.51 | $0.53 | 4 |
| 2028-03-31 | $0.40 | $0.42 | $0.44 | 5 |
| 2029-03-31 | $1.93 | $1.95 | $1.97 | 2 |
| 2030-03-31 | $2.30 | $2.41 | $2.50 | 1 |
Frequently Asked Questions
What is the analyst consensus for DOCS?
The consensus among 36 analysts covering Doximity, Inc. (DOCS) is Buy with an average price target of $42.79.
What is the highest price target for DOCS?
The highest price target for DOCS is $80.00, set by Scott Schoenhaus at KeyBanc on 2025-10-08.
What is the lowest price target for DOCS?
The lowest price target for DOCS is $25.00, set by Craig Hettenbach at Morgan Stanley on 2024-04-23.
How many analysts cover DOCS?
36 analysts have issued ratings for Doximity, Inc. in the past 12 months.
Is DOCS a buy or sell right now?
Based on 36 analyst ratings, DOCS has a consensus rating of Buy (2.47/5) with a +47.2% upside to the consensus target of $42.79.
What are the earnings estimates for DOCS?
Analysts estimate DOCS will report EPS of $0.34 for the period ending 2026-06-30, with revenue estimated at $154M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.